Exact Sciences Analyst Ratings
Gilead Sciences Trades in the Green for Seventh Straight Session
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Weight Loss Drug Developers Slump as Eli Lilly Slashes Cost of Some Zepbound Doses
Walgreens, Hims Stocks Drop as Lilly Rolls Out Cheap Weight-loss Drugs
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
Ready for Fed Rate Cuts? Biotech's Potential to Watch
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
AbbVie Unusual Options Activity For August 26
Update on Oppenheimer's Buy Vs. Sell SMID Ideas From Each of the Sectors
Guardant Health Falls 11% Amid ATM Stock Sale News
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Regeneron Highlights Scientific Innovation And Leadership In Respiratory Disease Management At ERS 2024, Featuring Dupixent And Itepekimab
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Regeneron Pharmaceuticals Analyst Ratings
AbbVie Analyst Ratings
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
In One Chart | Wall Street Eyes New Sectors for the Next Stock Market Surge